Valuation Metrics and Recent Changes
As of 15 Sep 2026, Crestchem’s price-to-earnings (P/E) ratio stands at 12.80, a figure that has contributed to the company’s reclassification from an attractive to a fair valuation grade. This P/E multiple is considerably lower than many of its peers in the specialty chemicals industry, where companies such as J.G. Chemicals and Titan Biotech trade at P/E ratios of 31.04 and 53.39 respectively. The relatively modest P/E suggests Crestchem remains reasonably priced, though the upward movement from previous levels indicates a moderation in bargain appeal.
The price-to-book value (P/BV) ratio of 4.32 further supports this shift. While a P/BV above 4 might appear elevated in absolute terms, it is consistent with the sector’s premium valuations driven by strong return metrics. Crestchem’s return on capital employed (ROCE) and return on equity (ROE) are impressive at 32.81% and 33.79% respectively, underscoring operational efficiency and effective capital utilisation that justify a premium valuation.
Comparative Analysis with Peers
When benchmarked against peers, Crestchem’s valuation appears more moderate. For instance, Oriental Aromatics trades at an exorbitant P/E of 338.09, reflecting either market exuberance or expectations of exceptional growth. Similarly, Indo Borax & Chemicals and Keltech Energies are classified as very expensive with P/E ratios of 31.85 and 45.08 respectively. In contrast, Crestchem’s EV to EBITDA multiple of 10.56 is significantly lower than these peers, indicating a more conservative enterprise valuation relative to earnings before interest, tax, depreciation and amortisation.
Moreover, Crestchem’s PEG ratio of 0.37 is notably attractive compared to the sector average, signalling that the stock’s price growth is not outpacing earnings growth excessively. This metric is a key indicator for investors seeking growth at a reasonable price, and Crestchem’s low PEG ratio suggests potential undervaluation relative to growth prospects.
Stock Price Performance and Market Context
The stock price of Crestchem has demonstrated resilience and outperformance relative to the broader market. Over the past week, Crestchem’s share price rose by 6.45%, while the Sensex declined by 2.27%. The one-month return of 12.2% starkly contrasts with the Sensex’s negative 4.32%, and year-to-date gains of 24.72% significantly outperform the benchmark’s 12.25% loss. Even over longer horizons, Crestchem’s three-year return of 110.24% dwarfs the Sensex’s 11.40% gain, highlighting sustained investor confidence and operational momentum.
Currently trading at ₹140.25, Crestchem is approaching its 52-week high of ₹154.55, having recovered strongly from a low of ₹73.01. The stock’s intraday volatility remains contained, with a trading range between ₹132.00 and ₹143.25 on the latest session, reflecting steady demand amid cautious optimism.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Implications of Valuation Grade Change
The upgrade in Crestchem’s mojo grade from Sell to Hold on 7 Sep 2026, accompanied by a mojo score of 50.0, reflects a tempered but positive reassessment of the stock’s investment merit. The shift from an attractive to a fair valuation grade signals that while the stock is no longer a deep value play, it remains a viable holding for investors seeking exposure to the specialty chemicals sector with reasonable risk.
Investors should note that Crestchem’s micro-cap status entails higher volatility and liquidity considerations compared to larger peers. However, the company’s strong profitability metrics and consistent returns on capital provide a solid foundation for sustainable growth. The dividend yield of 1.05% adds a modest income component, complementing capital appreciation potential.
Sector and Market Positioning
Within the specialty chemicals sector, Crestchem’s valuation multiples are positioned towards the lower end of the fair valuation spectrum. This contrasts with several peers classified as expensive or very expensive, suggesting Crestchem may offer a more balanced risk-reward profile. The company’s EV to capital employed ratio of 4.47 and EV to sales of 1.25 further indicate efficient capital deployment and revenue generation relative to enterprise value.
Given the sector’s cyclical nature and sensitivity to raw material costs and regulatory changes, Crestchem’s valuation moderation could also reflect cautious investor sentiment amid broader macroeconomic uncertainties. Nonetheless, the company’s operational metrics and relative valuation support a constructive outlook.
Holding Crestchem Ltd from Specialty Chemicals? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaway and Outlook
For investors analysing Crestchem Ltd, the recent valuation shift from attractive to fair should be viewed in the context of strong underlying fundamentals and sector dynamics. The company’s P/E ratio of 12.80 remains modest relative to many peers, while its robust ROCE and ROE ratios highlight operational excellence. The PEG ratio below 0.4 further suggests that earnings growth is not yet fully priced in, offering potential upside.
However, the narrowing margin of valuation attractiveness implies that investors should monitor price movements closely and consider relative valuations within the specialty chemicals sector. Crestchem’s micro-cap status and moderate dividend yield make it suitable for investors with a balanced risk appetite seeking growth with some income.
Overall, Crestchem’s valuation evolution reflects a maturing market perception, where the stock is transitioning from a deep value opportunity to a fair-value holding supported by solid financial metrics and sector tailwinds.
Historical Performance Context
Looking at longer-term returns, Crestchem has delivered exceptional gains, with a five-year return of 187.1% compared to the Sensex’s 28.26%. The three-year return of 110.24% also significantly outpaces the benchmark’s 11.40%. These figures underscore the company’s ability to generate shareholder value over time, reinforcing the rationale behind its current valuation levels.
Despite the recent price appreciation, Crestchem’s current price of ₹140.25 remains below its 52-week high of ₹154.55, suggesting some room for further upside if operational momentum continues and market conditions remain favourable.
Conclusion
Crestchem Ltd’s transition from an attractive to a fair valuation grade marks an important milestone in its market journey. While the stock no longer offers deep value pricing, its strong financial performance, reasonable multiples relative to peers, and impressive returns on capital justify a Hold rating. Investors should weigh the company’s micro-cap risks against its growth potential and sector positioning when considering portfolio allocation.
As the specialty chemicals sector evolves, Crestchem’s valuation metrics and market performance will remain key indicators for investors seeking to balance growth and valuation discipline in this dynamic industry.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
